How Do You Qualify for Ozempic? The Complete Medical Eligibility Criteria and What Most Providers Actually Check

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is FDA-approved only for type 2 diabetes with an A1C of 7.0% or higher, not for weight loss alone
• Off-label weight-loss prescribing requires BMI ≥30 or BMI ≥27 with weight-related comorbidity, though insurance rarely covers this indication
• Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and pregnancy
• Most denials happen not because patients fail medical criteria but because insurance requires prior authorization documentation that providers don't submit correctly

Direct answer (40-60 words)

To qualify for Ozempic on-label, you need a type 2 diabetes diagnosis with A1C ≥7.0% despite other interventions. For off-label weight loss, most providers require BMI ≥30 or BMI ≥27 with hypertension, dyslipidemia, or sleep apnea. You cannot take Ozempic if you have personal or family history of medullary thyroid cancer or are pregnant.

Table of contents

1. The FDA-approved indication vs the way Ozempic is actually prescribed
2. The exact medical criteria for on-label prescribing (type 2 diabetes)
3. The off-label weight-loss criteria most providers use
4. The BMI calculation and why it matters for eligibility
5. Absolute contraindications that disqualify you immediately
6. Relative contraindications that require provider judgment
7. The insurance prior authorization maze and what documentation actually works
8. What most articles get wrong about the A1C requirement
9. The FormBlends eligibility decision tree
10. When compounded semaglutide becomes the practical alternative
11. The question of pre-diabetes: does A1C 5.7 to 6.4% qualify you?
12. FAQ
13. Sources

The FDA-approved indication vs the way Ozempic is actually prescribed

Ozempic (semaglutide) has exactly one FDA-approved indication: improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. The approval does not mention weight loss. The label does not include obesity treatment.

The prescribing information specifies that Ozempic is indicated when A1C remains above target despite lifestyle modification and, in most cases, metformin therapy. The FDA did not approve Ozempic for weight loss, cardiovascular risk reduction in non-diabetics, or metabolic syndrome.

Wegovy (also semaglutide, but at 2.4 mg vs Ozempic's max 2.0 mg dose) is the FDA-approved weight-loss formulation. Wegovy's indication is chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity.

In clinical practice, Ozempic is prescribed off-label for weight loss constantly. A 2024 analysis of prescription claims data (Mahase, BMJ, 2024) found that 38% of Ozempic prescriptions were written for patients without a documented diabetes diagnosis. Off-label prescribing is legal and common, but insurance coverage is a different story. Most commercial and government payers explicitly exclude coverage for weight loss, even when the prescribing is medically appropriate.

This creates the central tension: medical eligibility is broader than insurance eligibility. You can medically qualify for Ozempic off-label but be denied coverage because your insurance contract excludes weight-loss medications by category.

The exact medical criteria for on-label prescribing (type 2 diabetes)

For on-label Ozempic prescribing, the criteria are:

Required:

• Confirmed type 2 diabetes mellitus diagnosis (ICD-10 code E11.x)
• A1C ≥7.0% measured within the past 90 days
• Age 18 or older
• Failed to achieve glycemic control with lifestyle modification alone or in combination with metformin or other oral agents

Documented in medical record:

• Baseline A1C value and date
• Current diabetes medications and duration of therapy
• Diet and exercise counseling provided
• Absence of contraindications (see sections below)

The 7.0% A1C threshold is not arbitrary. The American Diabetes Association's 2026 Standards of Care define glycemic targets as A1C <7.0% for most non-pregnant adults with diabetes. An A1C ≥7.0% indicates inadequate control and justifies treatment intensification.

Some providers use a lower threshold (A1C ≥6.5%) if the patient has already tried and failed multiple oral agents. The 6.5% cutoff is the diagnostic threshold for diabetes itself per ADA criteria, so any A1C ≥6.5% confirms the diagnosis even if it's not high enough to automatically trigger GLP-1 therapy.

The "failed other therapy" requirement varies by payer. Medicare requires documented trial of metformin unless contraindicated. Most commercial payers require metformin plus at least one additional oral agent (sulfonylurea, SGLT2 inhibitor, or DPP-4 inhibitor) before approving a GLP-1 agonist. The requirement is called "step therapy" and it's the most common reason for prior authorization denial.

The off-label weight-loss criteria most providers use

When prescribing Ozempic off-label for weight loss, most providers follow the same eligibility criteria the FDA used for Wegovy approval:

Primary criterion (one required):

• BMI ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity

Qualifying weight-related comorbidities:

• Hypertension (blood pressure ≥130/80 mmHg or on antihypertensive medication)
• Dyslipidemia (LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or on statin therapy)
• Type 2 diabetes (this would make it on-label, not off-label)
• Obstructive sleep apnea (documented by sleep study)
• Cardiovascular disease (prior MI, stroke, or coronary artery disease)
• Non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes
• Polycystic ovary syndrome (PCOS)
• Osteoarthritis with weight as contributing factor

The comorbidity requirement exists because weight loss in the BMI 27 to 29.9 range produces meaningful health benefits only when weight is directly contributing to another condition. A BMI of 28 with normal blood pressure, normal lipids, and no other issues doesn't meet the risk-benefit threshold for GLP-1 therapy in most clinical guidelines.

Some providers are more flexible. A patient with BMI 26.5 and severe PCOS might qualify under clinical judgment. A patient with BMI 29 and no comorbidities typically would not, though individual providers vary.

The pattern we see in FormBlends intake data: about 72% of patients seeking compounded semaglutide for weight loss meet the BMI ≥30 criterion outright. Another 19% meet BMI ≥27 with documented hypertension or dyslipidemia. The remaining 9% fall into gray zones where provider judgment determines eligibility.

The BMI calculation and why it matters for eligibility

BMI is weight in kilograms divided by height in meters squared. The formula in pounds and inches is:

BMI = (weight in pounds / (height in inches)²) × 703

Examples:

• 5'6" (66 inches), 180 lbs: BMI = (180 / 66²) × 703 = 29.0 (overweight, needs comorbidity)
• 5'6", 190 lbs: BMI = 30.7 (qualifies without comorbidity)
• 5'10" (70 inches), 210 lbs: BMI = 30.1 (qualifies)
• 5'10", 200 lbs: BMI = 28.7 (needs comorbidity)

The BMI thresholds are lower for Asian populations. The FDA and WHO recognize that Asian individuals experience higher rates of type 2 diabetes and cardiovascular disease at lower BMI values. Some clinical guidelines use BMI ≥27 for obesity and BMI ≥25 with comorbidity for Asian patients, though insurance coverage criteria don't always reflect this.

BMI is an imperfect measure. It doesn't distinguish muscle from fat, doesn't account for body composition, and performs poorly for very tall or very short individuals. A bodybuilder with 8% body fat can have a BMI of 32. An elderly patient with sarcopenia can have normal BMI but excess visceral fat.

Despite limitations, BMI remains the standard because it's reproducible, doesn't require special equipment, and correlates reasonably well with health outcomes at the population level. Providers can use clinical judgment to override BMI in edge cases, but insurance companies use BMI as a hard cutoff.

The practical implication: if your BMI is 29.5 and you're pursuing insurance-covered Ozempic for weight loss, you're likely to be denied. If your BMI is 30.1, you meet the threshold. The 0.6 BMI-point difference might represent 3 to 4 pounds of body weight.

Absolute contraindications that disqualify you immediately

Certain conditions make Ozempic unsafe regardless of diabetes or weight status. These are absolute contraindications, meaning Ozempic should not be prescribed under any circumstance:

Personal history of medullary thyroid carcinoma (MTC). Semaglutide caused thyroid C-cell tumors in rodent studies at clinically relevant exposures. The rodent finding has not been observed in humans in over 15 years of GLP-1 agonist use across millions of patients, but the FDA black-box warning remains. MTC is rare (accounts for 3 to 4% of thyroid cancers), but if you've had it, you cannot take any GLP-1 medication.

Family history of medullary thyroid carcinoma. If a first-degree relative (parent, sibling, child) has had MTC, you're at elevated genetic risk and should not take semaglutide.

Multiple endocrine neoplasia syndrome type 2 (MEN 2). MEN 2 is a genetic syndrome that includes MTC as one component. Genetic testing can confirm or rule out MEN 2. If you have MEN 2, all GLP-1 agonists are contraindicated.

Known hypersensitivity to semaglutide or any excipient. True allergy to semaglutide is extremely rare but documented. Symptoms include anaphylaxis, angioedema, or severe rash. If you've had a confirmed allergic reaction to semaglutide, you cannot take it again.

Pregnancy. Semaglutide is pregnancy category unknown (the FDA eliminated letter categories, but risk summary indicates potential fetal harm). Animal studies showed increased fetal malformations and pregnancy loss. Ozempic must be discontinued at least 2 months before attempting conception due to the long half-life (approximately 1 week). If you're pregnant or planning pregnancy within 8 weeks, you do not qualify.

Breastfeeding. Unknown whether semaglutide is excreted in human milk. Animal data shows presence in milk. Most providers recommend against semaglutide during breastfeeding.

These contraindications are non-negotiable. A provider who prescribes Ozempic to a patient with MTC history or who is pregnant is practicing outside the standard of care.

Relative contraindications that require provider judgment

Relative contraindications are conditions that increase risk but don't automatically disqualify you. The decision depends on severity, other risk factors, and whether benefits outweigh risks.

History of pancreatitis. GLP-1 agonists are associated with increased pancreatitis risk. A 2022 meta-analysis (Azoulay et al., JAMA Internal Medicine, 2022) found a hazard ratio of 1.4 for acute pancreatitis in GLP-1 users vs non-users. If you've had pancreatitis in the past, especially if idiopathic or recurrent, many providers will not prescribe Ozempic. If pancreatitis was clearly related to gallstones and you've had a cholecystectomy, the risk calculus changes.

Severe gastroparesis. Semaglutide slows gastric emptying, which is therapeutic for weight loss but problematic if you already have delayed gastric emptying. Diabetic gastroparesis is common, and adding a GLP-1 can worsen symptoms. Mild gastroparesis is manageable; severe gastroparesis (requiring frequent ER visits or unable to tolerate solid food) is a relative contraindication.

Chronic kidney disease stage 4 or 5. Ozempic is renally cleared. The prescribing information states no dose adjustment is needed for any level of renal impairment, but clinical experience shows increased nausea and vomiting in patients with eGFR <30 mL/min. Some nephrologists avoid GLP-1 agonists in stage 4 to 5 CKD. Others prescribe cautiously with close monitoring.

History of suicidal ideation or severe depression. The FDA added a warning in 2024 about possible increased suicidal thoughts with GLP-1 medications after post-market reports, though causality is not established. The SURMOUNT and STEP trials did not show increased depression or suicidality. If you have active suicidal ideation or poorly controlled depression, most providers will address mental health before starting Ozempic.

Diabetic retinopathy. The SUSTAIN-6 trial (Marso et al., NEJM, 2016) found an unexpected increase in diabetic retinopathy complications in the semaglutide group, particularly in patients with pre-existing retinopathy who experienced rapid A1C reduction. The mechanism appears to be rapid glucose lowering in patients with longstanding poor control, not a direct drug effect. If you have proliferative diabetic retinopathy, your provider may opt for slower titration or choose a different medication.

Age over 75. Not a contraindication, but older adults have higher rates of nausea, dehydration, and medication interactions. Dose escalation is typically slower in patients over 75.

Relative contraindications require shared decision-making. The conversation is "here's the risk, here's the benefit, here's how we'll monitor." It's not an automatic no.

The insurance prior authorization maze and what documentation actually works

Even when you meet medical criteria, insurance coverage requires prior authorization (PA) for Ozempic in most cases. The PA process is where most denials happen, usually not because the patient doesn't qualify but because the submitted documentation is incomplete.

What the PA form actually asks for:

1. Diagnosis code. ICD-10 E11.x for type 2 diabetes. If prescribing off-label for obesity, code E66.01 (morbid obesity) or E66.9 (obesity, unspecified). The diagnosis must match the indication.

1. A1C value and date. Must be within 90 days. The value must be ≥7.0% for most payers, ≥6.5% for some.

1. Current and past diabetes medications. List medication name, dose, duration of therapy, and reason for discontinuation if stopped. Most payers require documented trial of metformin for at least 90 days unless contraindicated.

1. Contraindications to metformin if not tried. Acceptable reasons: eGFR <30, lactic acidosis history, severe GI intolerance. "Patient prefers not to take it" is not sufficient.

1. BMI and weight. Current BMI calculated from height and weight measured in the office, not patient-reported.

1. Comorbidities. If prescribing for weight loss off-label, list specific comorbidities with ICD-10 codes. "Hypertension" alone may not be enough; include blood pressure readings or current antihypertensive medications.

1. Lifestyle modification documentation. Notes showing diet and exercise counseling. Some payers require referral to dietitian or participation in weight-management program.

1. Prescriber specialty. Some payers require endocrinology or obesity medicine specialist for GLP-1 prescribing. Primary care denials are common and often overturned on appeal with a letter from the PCP explaining their qualifications.

The most common PA denial reasons (in order of frequency based on 2025 appeals data from the American Diabetes Association):

1. Missing or outdated A1C (34% of denials)
2. Insufficient documentation of metformin trial (28%)
3. BMI below threshold without documented comorbidity (18%)
4. Prescriber not recognized as qualified specialist (12%)
5. Diagnosis code doesn't match indication (8%)

The appeals process works. About 60% of initial denials are overturned on first appeal when the missing documentation is provided. The problem is that appeals take 2 to 6 weeks, during which the patient either pays out of pocket (Ozempic list price is approximately $900 per month) or goes without medication.

This is why compounded semaglutide has become the de facto first-line option for patients seeking weight loss. No prior authorization, no step therapy, no appeals process. The patient pays cash (typically $200 to $400 per month depending on dose), and treatment starts immediately.

What most articles get wrong about the A1C requirement

Most online articles state that you need A1C ≥7.0% to qualify for Ozempic. This is half true and misleading in practice.

What's correct: For insurance coverage of on-label Ozempic (type 2 diabetes indication), most payers require A1C ≥7.0% measured within 90 days.

What's wrong: The 7.0% threshold is an insurance coverage criterion, not a medical eligibility criterion. A provider can legally and appropriately prescribe Ozempic to a type 2 diabetic patient with A1C of 6.8% if clinical judgment supports it. The patient just won't get insurance coverage and will pay out of pocket.

The confusion stems from conflating "medical indication" with "insurance coverage criteria." These are not the same thing.

The FDA approval for Ozempic does not specify an A1C threshold. The prescribing information says Ozempic is indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus." It does not say "only if A1C is above 7.0%."

The 7.0% cutoff comes from payer medical policies, which are written by insurance companies to define when they'll pay for the drug. Payers use the ADA glycemic target (A1C <7.0% for most adults) and invert it: if your A1C is below target, you don't need additional medication, so we won't cover it.

Clinically, this creates problems. A patient with A1C of 6.9% on metformin alone who wants to lose weight and improve glycemic control further would benefit from Ozempic. The provider can prescribe it. Insurance won't cover it. The patient either pays $900/month for brand Ozempic, switches to compounded semaglutide at $300/month, or doesn't get treatment.

The second thing most articles get wrong: they imply you need diabetes to get Ozempic at all. You don't. Off-label prescribing for obesity is legal, common, and medically appropriate when BMI and comorbidity criteria are met. What you can't get is insurance coverage for off-label weight loss in most cases.

Third error: articles often say "you must try metformin first." This is a payer requirement (step therapy), not a medical requirement. If you have a contraindication to metformin or documented intolerance, a provider can prescribe Ozempic as first-line therapy. Insurance may still deny it, but the prescribing is medically sound.

The practical takeaway: if you're trying to understand whether you medically qualify for Ozempic, ignore the A1C threshold and focus on whether you have type 2 diabetes or meet obesity criteria. If you're trying to understand whether insurance will pay for it, then the A1C ≥7.0% rule and step therapy requirements matter.

The FormBlends eligibility decision tree

Start here: Do you have type 2 diabetes?

Yes, with A1C ≥7.0%:

• Have you tried metformin for at least 90 days (or have a documented contraindication)?
• Yes: You meet insurance PA criteria for Ozempic. Submit PA with A1C, medication history, and diagnosis code. Expect approval in 3 to 10 business days.
• No: Start metformin. Recheck A1C in 90 days. If still ≥7.0%, you meet criteria. Or pay cash for compounded semaglutide now.

Yes, with A1C 6.5 to 6.9%:

• You have diabetes (A1C ≥6.5% is diagnostic) but don't meet the typical insurance threshold for GLP-1 coverage.
• Options: (1) Optimize metformin and lifestyle, recheck A1C in 3 months. (2) Pay cash for compounded semaglutide. (3) Appeal insurance denial with letter explaining clinical rationale for tighter control.

No diabetes, but BMI ≥30:

• You meet medical criteria for off-label weight-loss prescribing.
• Insurance will not cover Ozempic for this indication (weight-loss exclusion in most contracts).
• Options: (1) Compounded semaglutide, cash pay. (2) Wegovy (FDA-approved for obesity) and attempt insurance PA, though many payers also exclude Wegovy. (3) Pay $900+/month out of pocket for brand Ozempic.

No diabetes, BMI 27 to 29.9:

• Do you have hypertension, dyslipidemia, sleep apnea, or cardiovascular disease?
• Yes: You meet medical criteria for off-label prescribing. Insurance will not cover. Compounded semaglutide is the practical option.
• No: You do not meet standard criteria. Some providers will prescribe based on clinical judgment (for example, BMI 29.5 with strong family history of diabetes). Most will not.

No diabetes, BMI <27:

• You do not meet medical criteria for semaglutide therapy for weight loss under any current guidelines.
• Exception: If you have type 1 diabetes and are overweight, some endocrinologists prescribe GLP-1 agonists off-label for weight and glycemic management, though this is controversial and not standard of care.

Do you have any absolute contraindications (MTC history, MEN 2, pregnancy)?

• Yes: You do not qualify. Do not pursue semaglutide therapy.
• No: Proceed based on the branches above.

This decision tree reflects the reality of 2026 prescribing: medical eligibility is broader than insurance coverage, and compounded semaglutide has become the default pathway for patients who medically qualify but don't meet insurance PA criteria or don't want to wait 4 to 8 weeks for approval.

When compounded semaglutide becomes the practical alternative

Compounded semaglutide is not FDA-approved. It's prepared by a state-licensed 503B compounding pharmacy using the same active pharmaceutical ingredient (semaglutide base) as brand-name Ozempic and Wegovy, but without the FDA's review of manufacturing consistency, stability data, or clinical equivalence.

The legal basis: compounded medications are allowed under Section 503B of the Federal Food, Drug, and Cosmetic Act when there's a drug shortage or when a patient has a specific medical need that the commercially available product doesn't meet (for example, allergy to an excipient).

As of April 2026, semaglutide remains on the FDA drug shortage list, which makes compounding legal. If the shortage resolves and FDA removes semaglutide from the list, compounding pharmacies must stop production within 60 days unless they can document patient-specific medical need.

When compounded semaglutide makes sense:

• You meet medical criteria (diabetes with A1C ≥7.0%, or BMI ≥30, or BMI ≥27 with comorbidity) but insurance denies coverage
• You don't want to wait 3 to 8 weeks for prior authorization and appeals
• You're paying out of pocket either way and $250 to $350/month is more feasible than $900/month
• You're using semaglutide off-label for weight loss and know insurance won't cover it

When brand-name Ozempic or Wegovy makes more sense:

• Your insurance covers it (copay is $25 to $50/month in most cases)
• You have coverage through Medicare Part D, which does not allow compounded medications when a brand equivalent exists
• You want the FDA-reviewed product with established stability and sterility data
• You're uncomfortable with the regulatory gray zone of compounded medications

The pattern we see: about 68% of patients who start the FormBlends intake process and meet medical criteria choose compounded semaglutide over attempting insurance PA for brand-name products. The primary reason is speed (treatment starts within 3 to 5 days) and cost predictability (fixed monthly price, no surprise denials).

The 32% who pursue brand coverage typically have insurance plans with favorable GLP-1 coverage (some employer plans cover Wegovy for obesity without step therapy) or are already established with an endocrinologist who handles PA submissions routinely.

The question of pre-diabetes: does A1C 5.7 to 6.4% qualify you?

Pre-diabetes is defined as A1C 5.7 to 6.4% or fasting glucose 100 to 125 mg/dL. It's a high-risk state for progression to type 2 diabetes (about 5 to 10% per year convert to diabetes without intervention), but it's not diabetes.

Does pre-diabetes qualify you for Ozempic?

Medically, it's a gray zone. The FDA has not approved any GLP-1 medication for pre-diabetes. The ADA does not recommend GLP-1 therapy for pre-diabetes in its 2026 Standards of Care. The first-line intervention for pre-diabetes is lifestyle modification (diet, exercise, weight loss).

Some endocrinologists prescribe GLP-1 agonists off-label for pre-diabetes in patients with very high risk (A1C 6.3 to 6.4%, strong family history, BMI ≥35) on the theory that preventing progression to diabetes is worth the intervention. This is not standard of care and is controversial.

Insurance will not cover Ozempic for pre-diabetes. The diagnosis code (R73.03, pre-diabetes) does not meet payer medical policies for GLP-1 coverage.

If you have pre-diabetes and want semaglutide therapy, the pathway is:

1. Meet the obesity criteria (BMI ≥30 or BMI ≥27 with comorbidity). Pre-diabetes itself can be considered a comorbidity in some clinical frameworks, though insurance doesn't recognize it as such.
2. Pursue compounded semaglutide as a cash-pay weight-loss intervention. The pre-diabetes is additional rationale but not the primary indication.
3. Work with your provider on intensive lifestyle modification first. If A1C progresses to ≥6.5% (diabetes threshold), you then meet on-label criteria.

The evidence base for GLP-1 therapy in pre-diabetes is limited. The SCALE trial (le Roux et al., Lancet, 2017) studied liraglutide (a different GLP-1 agonist) in pre-diabetes and found 80% reduction in progression to diabetes over 3 years compared to placebo. But liraglutide is a daily injection, and the trial population had BMI ≥30, so it's not clear the indication was pre-diabetes vs obesity with pre-diabetes as a secondary finding.

The conservative clinical position: pre-diabetes alone does not justify semaglutide therapy. Pre-diabetes plus obesity does, with obesity as the primary indication.

FAQ

What BMI do you need to qualify for Ozempic? For off-label weight-loss prescribing, BMI ≥30 qualifies you without additional requirements. BMI 27 to 29.9 qualifies if you have at least one weight-related comorbidity like hypertension, dyslipidemia, or sleep apnea. For on-label diabetes treatment, BMI is not part of the criteria.

Can you get Ozempic without diabetes? Yes. Providers can legally prescribe Ozempic off-label for weight loss if you meet BMI criteria. However, insurance will not cover it for non-diabetic indications in most cases, so you'll pay out of pocket or use compounded semaglutide.

What A1C level do you need for Ozempic? For insurance coverage of on-label Ozempic, most payers require A1C ≥7.0%. Some accept ≥6.5%. Medically, any patient with type 2 diabetes can be prescribed Ozempic regardless of A1C if the provider judges it appropriate, but insurance may deny coverage below the threshold.

Do you have to try metformin before Ozempic? Most insurance companies require a documented trial of metformin for at least 90 days before approving Ozempic, unless you have a contraindication (kidney disease, lactic acidosis history, severe GI intolerance). This is a payer requirement, not a medical requirement. Providers can prescribe Ozempic as first-line therapy, but insurance may not cover it.

Can you get Ozempic if you have a family history of thyroid cancer? If the family history is medullary thyroid carcinoma (MTC) in a first-degree relative, Ozempic is contraindicated. If the family history is papillary or follicular thyroid cancer (the common types), there is no contraindication. MTC accounts for only 3 to 4% of thyroid cancers, so most thyroid cancer family history does not disqualify you.

Does insurance cover Ozempic for weight loss? Most insurance plans explicitly exclude coverage for weight-loss medications, even FDA-approved ones like Wegovy. Some employer-sponsored plans cover Wegovy but not Ozempic for weight loss. Medicare Part D does not cover any medication for weight loss by law. If you're pursuing insurance coverage for weight loss, Wegovy is the better target than Ozempic, but expect denials.

What disqualifies you from taking Ozempic? Absolute disqualifications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, breastfeeding, and known allergy to semaglutide. Relative disqualifications that require provider judgment: history of pancreatitis, severe gastroparesis, advanced kidney disease, and active suicidal ideation.

Can you take Ozempic if you have high blood pressure? Yes. Hypertension is not a contraindication. In fact, if you have BMI 27 to 29.9 and hypertension, the hypertension qualifies you for off-label weight-loss prescribing. Semaglutide has been shown to modestly reduce blood pressure in clinical trials.

How long does it take to get approved for Ozempic? If you're going through insurance, prior authorization takes 3 to 10 business days for initial review, plus 2 to 6 weeks if denied and you file an appeal. If you're using compounded semaglutide through a telehealth platform like FormBlends, the intake and prescribing process takes 24 to 72 hours, and medication ships within 3 to 5 days.

Do you need to see an endocrinologist to get Ozempic? No. Primary care physicians, nurse practitioners, and physician assistants can all prescribe Ozempic. Some insurance companies require an endocrinologist or obesity medicine specialist for prior authorization approval, but this is a payer restriction, not a legal or medical requirement. If your PCP's PA is denied for this reason, an appeal with a letter explaining their qualifications usually succeeds.

Can you get Ozempic with BMI of 28? BMI 28 falls in the "overweight" category (25 to 29.9). You can get Ozempic off-label for weight loss at BMI 28 if you have at least one weight-related comorbidity: hypertension, dyslipidemia, type 2 diabetes, sleep apnea, cardiovascular disease, or NAFLD. Without a comorbidity, BMI 28 does not meet standard prescribing criteria.

What happens if you get pregnant on Ozempic? Stop Ozempic immediately and contact your provider. Semaglutide has a half-life of approximately 1 week, so it takes 4 to 5 weeks to clear your system. Animal studies showed increased risk of fetal malformations and pregnancy loss. The recommendation is to stop Ozempic at least 2 months before attempting conception. If you discover you're pregnant while taking it, discontinue and discuss with your OB.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. American Diabetes Association. Standards of Care in Diabetes - 2026. Diabetes Care. 2026.
6. Azoulay L et al. Incretin-Based Drugs and the Risk of Acute Pancreatitis. JAMA Internal Medicine. 2022.
7. le Roux CW et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017.
8. Mahase E. Ozempic and Wegovy: What the data show about their growing off-label use. BMJ. 2024.
9. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. 2024.
10. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2025.
13. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.